N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
N/A N=5,970 Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs
Colorectal Cancer
Primary: Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem…
N/A N=264 Colorectal Cancer Screening Assessment Study
Colorectal Cancer
Primary: Use of FOBT ColoCARE Home Kit — 14; 2; 14; 0 participants
N/A N=41,193 Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Colorectal Cancer
Primary: FIT Completion — 10.4; 13.9 Model based percentage of participants — p=.05
N/A N=11,016 Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Colorectal Neoplasms · Digestive System Diseases · Colonic Diseases
Primary: Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. — 92.3; 73.8; 93.3; 73.3 percent
Phase 2 N=79 Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
Colon Cancer · Precancerous Condition · Rectal Cancer
Primary: Change of a Spectral Biomarker for Colonic Carcinogenesis (Called Spectral Slope or SPEC) From Baseline to 3 Months. — 40.72; 37.54; 43.45; 37.52 micron^-1 — p=0.11
N/A N=404 Interventions to Improve Colorectal Cancer Screening
Colorectal Neoplasms
Primary: Colorectal Cancer Screening — 127; 112 participants — p=0.01
N/A N=35 Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer
Healthy Subject
Primary: Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators) — 14; 15; 1; 1 Participants
N/A N=1,111 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Cancer Screening Tests
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 110; 95; 113; 113 Participants
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
N/A N=1,855 The Colorectal Breath Analysis (COBRA) Study
Colorectal Cancer · Colorectal Polyps · Colorectal Adenocarcinoma
Primary: Determine the Diagnostic Accuracy of the Proposed Breath Test for Detection of Colorectal Cancer in All Patients — 79; 86 percentage of true cases
N/A N=14,263 Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
N/A N=100 Screen to Save: A Colorectal Cancer Educational Intervention
Colorectal Cancer
Primary: Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening — 1 score on a scale — p=0.0001
N/A N=82 Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
Colorectal Cancer Screening
Primary: Facilitators and Barriers to Implementing Decision Aids, Provider Notifications, and Personal Risk Calculation Using an Electronic Health Record (EHR) to Promote…
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
N/A N=825 Shared Decision-Making for Colorectal Cancer Screening
Colorectal Cancer
Primary: Patient Adherence (Test Completion) — 104; 116; 96 participants — p=0.046
Phase 3 N=566 Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening
Colorectal Cancer
Primary: Colorectal Cancer (CRC) Screening Completion — 17; 69 participants — p=0.32
N/A N=450 Improving Rates of Repeat Colorectal Cancer Screening
Colorectal Neoplasms
Primary: Completion of a Fecal Occult Blood Test (FOBT) — 185; 84 participants
N/A N=35 Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma
Colorectal Adenoma · Risk Reduction
Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells
N/A N=998 Colorectal Cancer Screening in Alaska Native Men
Colorectal Cancer
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 11; 16; 18; 19 Participants
Phase 2 N=17 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
N/A N=5,696 Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
Colorectal Carcinoma
Primary: Likelihood of Any Colorectal Cancer (CRC) Screening (for Study-eligible Patients) — 11.8; 4.5 Percentage of participants
Phase 2 N=75 Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
N/A N=2,600 The National CT Colonography Trial
Colorectal Cancer
Primary: Number of Participants With Advanced Adenomas (>=10mm) as Determined by Colonoscopy (Per Patient) — 109; 2422 Participants
Phase 2 N=27 Regorafenib in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Phase 2 N=24 Trial of Aspirin and Arginine Restriction in Colorectal Cancer
Colorectal Cancer
Primary: Rectal Tissue Putrescine Reduction — 17 Participants
N/A N=801 U01 CRC Project for Vietnamese Americans
Colorectal Cancer
Primary: Colorectal Cancer Screening Rate — 333; 162 Participants